Advertisement
Table 3 Treatment characteristics
| Trial ID | Molecular Weight | Cross-Linked | Production method | Injection technique | Injection regimen |
|---|---|---|---|---|---|
| Altman, 2004 | High | Yes | Bio-HA | NR | Single 60 mg/3 ml injection of IA-HA or saline |
| Altman, 2009 | High | No | Bio-HA | Suprapatellar or infrapatellar approach | 3 weekly injections of IA-HA (20 mg/2 ml) or saline |
| Arden, 2014 | High | Yes | Bio-HA | Lateral midpatellar, lateral upper-patellar or medial | Single 3 ml injectionof IA-HA (60 mg/3 ml) or saline |
| Brandt, 2001 | Moderate | No | Bio-HA | NR | 3 weekly injections of IA-HA (2 ml; 15 mg/ml) or saline (2 ml) |
| Chevalier, 2010 | High | Yes | ADHA | NR | Single 6 ml injectionof IA-HA or saline |
| Creamer, 1994 | Low | No | ADHA | NR | Single injection of HA (20 mg/2 ml) into one knee and saline (2 ml) into the other |
| Day, 2004 | Low | No | ADHA | Lateral or medial approach | 5 weekly injections of 25 mg/2.5 ml IA-HA in a phosphate buffered solution or 2.5 ml vehicle or saline |
| DeCaria, 2012 | Low | No | NR | Anteromedial approach | 3 weekly injections of IA-HA (2 ml of 20 mg/ml), or saline (1.2 ml of 0.001 mg/ml HA) |
| Diracoglu, 2009 | High | Yes | ADHA | NR | 3 weekly injections of IA-HA or saline |
| Dixon, 1988 | Low | No | ADHA | NR | Up to 11 injections of IA-HA (20 mg/2 ml) or placebo (0.2 mg sodium hyaluronate) |
| Henderson, 1994 | Low | No | ADHA | Medial approach | 5 weekly injections of IA-HA (20 mg/2 ml) or saline |
| Huang, 2011 | Low | No | ADHA | NR | 5 weekly injections of IA-HA (20 mg/2 ml) or saline |
| Huskisson, 1999 | Low | No | ADHA | NR | 5 weekly injections of IA-HA (20 mg/2 ml) or saline |
| Jorgensen, 2010 | Low | No | ADHA | Lateral parapatellar approach | 5 weekly injections of IA-HA (20 mg/2 ml) or saline |
| Karlsson, 2002 | High | Yes | ADHA | NR | 3 weekly injections of IA-HA (Artzal, 2.5 ml or Synvisc, 2.0 ml) or saline |
| Kotevoglu, 2006 | High | Yes | ADHA | Anterolateral approach | 3 weekly injections of IA-HA or saline |
| Lohmander, 1996 | Low | No | ADHA | NR | 5 weekly injections of IA-HA (25 mg/2.5 ml) or saline |
| Lundsgaard, 2008 | Low | No | ADHA | Lateral midpatellar portal | 4 weekly intra-articular injections of IA-HA 2 mL (Hyalgan, 10.3 mg/ml) versus physiological saline 20 ml (distention) versus physiological saline 2 ml |
| Navarro-Sarabia 2011 | Low | No | Bio-HA | NR | 4 treatment cycles of 5 weekly injections of IA-HA or saline (2.5 ml) |
| Neustadt, 2005 | Moderate | No | Bio-HA | Lateral or medial approach | 4 weekly injections of IA-HA (30 mg/2 ml), or 4 arthrocenteses without injection (control) |
| Petrella, 2006 | Low | no | ADHA | NR | 3 weekly injections of IA-HA (20 mg/ml) or saline |
| Petrella, 2008 | High | No | ADHA | Medial approach | 3 weekly injections of IA-HA or saline |
| Pham, 2004 | NR | NR | NR | NR | 3 weekly injections of IA-HA or saline |
| Puhl, 1993 | High | No | ADHA | NR | 5 weekly injections of IA-HA (25 mg/2.5 ml) or dilute IA-HA control(0.25 mg/2.5 ml HA) |
| Scale, 1994 | High | No | ADHA | NR | Two intra-articular injections of IA-HA (2.0 ml) administered 2 weeks apart were compared with three intra-articular injections of IA-HA given 1 week apart vs saline (2.0 ml) |
| Sezgin, 2005 | Moderate | No | Bio-HA | NR | 3 weekly injections of IA-HA (15 mg/ml) or saline |
| Strand, 2012 | High | Yes | ADHA | NR | Single 3 ml injection of IA-HA (30 mg/3.0 ml) or saline |
| Tamir, 2001 | High | No | Bio-HA | NR | 5 weekly injections of 20 mg IA-HA (10 mg/ml) or saline |
| van der Weegen, 2015 | Low | Yes | Bio-HA | NR | 3 weekly injections of IA-HA (15 mg/ml) or saline |
| Wobig, 1998 | High | Yes | ADHA | NR | 3 weekly injections of 2.0 ml IA-HA or saline |
